Nestle Health Science US Holdings, Inc. 4
4 · Aimmune Therapeutics, Inc. · Filed Apr 24, 2020
Insider Transaction Report
Form 4
Transactions
- Purchase
Common Stock
2018-02-26$32.00/sh+937,500$30,000,000→ 8,489,584 total(indirect: See Footnote) - Purchase
Common Stock
2018-11-28$30.27/sh+3,237,529$98,000,003→ 11,727,113 total(indirect: See Footnote)
Footnotes (2)
- [F1]Consists of 8,489,584 shares of Common Stock held by Nestle Health Science US Holdings, Inc. ("NHS"). NHS is a wholly owned subsidiary of NIMCO US, Inc. ("NIMCO"). The ultimate parent company of NHS and NIMCO is Nestle S.A. ("Nestle"). Each of these entities may be deemed to share voting and investment power with respect to all shares of Common Stock held by NHS. Each of NIMCO and Nestle disclaims beneficial ownership of such shares of Common Stock except to the extent of its pecuniary interest therein.
- [F2]Consists of 11,727,113 shares of Common Stock held by Nestle Health Science US Holdings, Inc. ("NHS"). NHS is a wholly owned subsidiary of NIMCO US, Inc. ("NIMCO"). The ultimate parent company of NHS and NIMCO is Nestle S.A. ("Nestle"). Each of these entities may be deemed to share voting and investment power with respect to all shares of Common Stock held by NHS. Each of NIMCO and Nestle disclaims beneficial ownership of such shares of Common Stock except to the extent of its pecuniary interest therein.